Thermo Fisher Scientific Reports $42.88 Billion Revenue for 2024 in New Strategic Analysis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Globenewswire
- Company Overview: Founded in 1956, Thermo Fisher Scientific has emerged as a global leader in scientific instrumentation and biopharma services, reporting $42.88 billion in revenue for 2024, reflecting strong demand across its diversified product portfolio.
- Product Portfolio Highlights: The company’s offerings span four major segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products, supporting global research institutions and pharmaceutical companies, thereby enhancing its market position in biomanufacturing and precision medicine.
- Innovation and R&D: Thermo Fisher continues to drive innovation across all four business segments, particularly in clinical diagnostics and next-generation sequencing technologies, launching key products like rapid influenza tests that further solidify its market leadership.
- Sustainability Strategy: The company is committed to sustainability, investing in environmental impact goals and ethical sourcing initiatives aimed at reducing global emissions and improving healthcare equity, reflecting its dedication to corporate responsibility.
Analyst Views on TMO
Wall Street analysts forecast TMO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TMO is 658.89 USD with a low forecast of 580.00 USD and a high forecast of 750.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Analyst Rating
18 Buy
1 Hold
0 Sell
Strong Buy
Current: 624.650
Low
580.00
Averages
658.89
High
750.00
Current: 624.650
Low
580.00
Averages
658.89
High
750.00
About TMO
Thermo Fisher Scientific Inc. is engaged in accelerating life sciences research, solving complex analytical challenges, increasing laboratory productivity, and improving patient health through diagnostics and the development and manufacture of life-changing therapies. Through its Life Sciences Solutions segment, it provides a portfolio of reagents, instruments and consumables used in biological and medical research, the discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. Through its Analytical Instruments segment, it provides instruments and the supporting consumables, software and services that are used for a range of applications. Its Specialty Diagnostics segment offers a range of diagnostic test kits, reagents, culture media, instruments and associated products. Its Laboratory Products and Biopharma Services segment offers virtually everything needed for the laboratory. It also provides purification and filtration technologies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
